PMID- 28219345
OWN - NLM
STAT- MEDLINE
DCOM- 20171121
LR  - 20220310
IS  - 1471-2369 (Electronic)
IS  - 1471-2369 (Linking)
VI  - 18
IP  - 1
DP  - 2017 Feb 20
TI  - Biomarkers for the detection of renal fibrosis and prediction of renal outcomes: 
      a systematic review.
PG  - 72
LID - 10.1186/s12882-017-0490-0 [doi]
LID - 72
AB  - BACKGROUND: Fibrosis is the unifying pathway leading to chronic kidney disease. 
      Identifying biomarkers of fibrosis may help predict disease progression. METHODS: 
      We performed a systematic review to evaluate the reliability of blood and urine 
      biomarkers in identifying fibrosis on biopsy as well as predicting renal 
      outcomes. Using MEDLINE and EMBASE, a two-stage search strategy was implemented. 
      Stage I identified a library of biomarkers correlating with fibrosis on biopsy. 
      Stage II evaluated the association between biomarkers identified in stage I, and 
      renal outcomes. Only biomarkers with moderate positive correlation with fibrosis 
      (r > 0.40) or acceptable area under the curve (AUC >0.65) advanced to stage II. 
      RESULTS: Stage I identified 17 studies and 14 biomarkers. Five biomarkers met 
      criteria to advance to stage II, but only three were independently associated 
      with renal outcomes. Transforming growth factor beta (TGF-beta) correlated with 
      fibrosis (r = 0.60), and was associated with 1.7-3.9 times the risk of worsening 
      renal function in 426 patients. Monocyte chemoattractant protein-1 (MCP-1) 
      diagnosed fibrosis with AUC of 0.66 and was associated with 2.3-11.0 times the 
      risk of worsening renal function in 596 patients. Matrix metalloproteinase-2 
      (MMP-2) correlated with fibrosis (r = 0.41), and was associated with 2.5 times 
      the risk of worsening renal function. CONCLUSIONS: Given the heterogeneity of the 
      data due to diverse patient populations along with differing renal outcomes, a 
      meta-analysis could not be conducted. Nonetheless we can conclude from the 
      published data that TGF-beta, MCP-1 and MMP-2 may identify patients at risk for 
      renal fibrosis and hence worse renal outcomes.
FAU - Mansour, Sherry G
AU  - Mansour SG
AD  - Program of Applied Translational Research, Department of Medicine, Yale 
      University, School of Medicine, New Haven, CT, USA.
AD  - Section of Nephrology, Yale University School of Medicine, 60 Temple Street, 
      Suite 6C, New Haven, CT, 06510, USA.
FAU - Puthumana, Jeremy
AU  - Puthumana J
AD  - Program of Applied Translational Research, Department of Medicine, Yale 
      University, School of Medicine, New Haven, CT, USA.
FAU - Coca, Steven G
AU  - Coca SG
AD  - Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount 
      Sinai, New York, NY, USA.
FAU - Gentry, Mark
AU  - Gentry M
AD  - Harvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, CT, 
      USA.
FAU - Parikh, Chirag R
AU  - Parikh CR
AD  - Program of Applied Translational Research, Department of Medicine, Yale 
      University, School of Medicine, New Haven, CT, USA. chirag.parikh@yale.edu.
AD  - Section of Nephrology, Yale University School of Medicine, 60 Temple Street, 
      Suite 6C, New Haven, CT, 06510, USA. chirag.parikh@yale.edu.
AD  - Veterans Affairs Connecticut Healthcare System, New Haven, CT, USA. 
      chirag.parikh@yale.edu.
LA  - eng
GR  - T32 DK007276/DK/NIDDK NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20170220
PL  - England
TA  - BMC Nephrol
JT  - BMC nephrology
JID - 100967793
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Transforming Growth Factor beta)
RN  - EC 3.4.24.24 (MMP2 protein, human)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
SB  - IM
MH  - Area Under Curve
MH  - Biomarkers/*metabolism
MH  - Chemokine CCL2/*metabolism
MH  - Disease Progression
MH  - Fibrosis
MH  - Humans
MH  - Kidney/*pathology
MH  - Kidney Diseases/*metabolism
MH  - Matrix Metalloproteinase 2/*metabolism
MH  - Prognosis
MH  - Reproducibility of Results
MH  - Transforming Growth Factor beta/*metabolism
PMC - PMC5319065
OTO - NOTNLM
OT  - Biomarkers
OT  - Chronic kidney disease
OT  - Fibrosis
OT  - Outcomes
OT  - Renal biopsy
OT  - Renal disease progression
EDAT- 2017/02/22 06:00
MHDA- 2017/11/29 06:00
PMCR- 2017/02/20
CRDT- 2017/02/22 06:00
PHST- 2016/09/11 00:00 [received]
PHST- 2017/02/14 00:00 [accepted]
PHST- 2017/02/22 06:00 [entrez]
PHST- 2017/02/22 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/02/20 00:00 [pmc-release]
AID - 10.1186/s12882-017-0490-0 [pii]
AID - 490 [pii]
AID - 10.1186/s12882-017-0490-0 [doi]
PST - epublish
SO  - BMC Nephrol. 2017 Feb 20;18(1):72. doi: 10.1186/s12882-017-0490-0.